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THE NATURE OF PROBLEM BACTERIA: IS RESISTANCE ENOUGH?
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Over the past 4 years, a variant subpopulation of Staphylococcus aureus has been characterized
that is defective in electron transport. These organisms grow slowly and are typical of the previously
described small colony variants (SCVs). Indeed, many earlier papers included data that are consis-
tent with defective respiratory activity in SCVs. We present a hypothesis that serves as biochemical
basis for the development of SCVs. These variants are particularly interesting because they have
been associated with very persistent infections, and they are more resistant to many antibiotics
than normal S. aureus. Because of their slow growth, atypical colonial morphology, and unusual
biochemical profile, they are easily missed or misidentified in the clinical laboratory. This is of some
significance, as this subpopulation is more resistant to antibiotics than the parent population from
which they arose. When an infection is particularly resistant to therapy, persists for a long period,
or fails to respond to apparently adequate antimicrobial therapy, clinicians and clinical laboratory
personnel should consider special efforts to search for SCVs.
Staphylococci are some of the most feared pathogens be- negative staphylococci [5]. A number of recent articles have
addressed the problem of staphylococcal antibiotic resistancecause of their ability to cause overwhelming sepsis and death.
While many of these fears were alleviated with the advent of from the standpoint of classic forms of resistance, e.g., enzy-
matic degradation (production of b-lactamases and aminogly-antibiotics, the emergence of staphylococci resistant to multiple
antibiotics has renewed concern and led to the featuring of coside modifying enzymes), altered penicillin-binding proteins
(methicillin resistance), and enhanced export (quinolones) [4,these organisms in both the lay [1, 2] and biomedical press
[3–7] as a new threat in the postantibiotic era. Because vanco- 6–9]; however, staphylococci may have additional mechanisms
for resisting therapy that extend beyond these classic mecha-mycin is the only drug with dependable activity against methi-
cillin-resistant strains of Staphylococcus aureus [4, 6, 7], the nisms. In this review, we will present a hypothesis concerning
a biochemical basis for the development of ‘‘phenotypic resis-emergence of some strains of S. aureus with intermediate resis-
tance to vancomycin has heightened the fears of a pan antibi- tance,’’ wherein a subpopulation of organisms occurs as slow-
growing variants that are more resistant than the original popu-otic-resistant strain [3]. These concerns are reinforced by the
existence of a number of species of gram-positive cocci that lation to many commonly used antibiotics.
are vancomycin resistant, including some strains of coagulase-
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were b-lactamase producers. His ankle apparently was still hemin biosynthesis will be auxotrophs and will be deficient in
electron transport.infected with a staphylococcal strain from the 1940s.
This case raises several questions. Where did the bacteria Reduced electron transport results in multiple phenotypic
changes. Interruption of electron transport results in a decreasedpersist? What mechanisms allowed them to resist antibiotic
therapy? What were the signaling mechanisms for the bacteria electrochemical gradient and reduced quantities of adenosine
triphosphate (ATP). Because ATP is used in so many cellularto become reactivated? Why must staphylococcal infections be
treated for so much longer than other gram-positive bacterial reactions, the phenotype of menadione or hemin auxotrophic
S. aureus SCVs differs markedly from that of the parent strain.infections to achieve a cure? How can such a virulent organism
persist without causing symptoms for so many years? Answers At 18 hours, the colonies are very small, nonpigmented, and
nonhemolytic [54–59]. SCVs have a weak coagulase reactionto some of these questions may relate to more recent data on
variant forms of staphylococci that may resist antibiotic therapy which may take 18–24 hours to become positive. Large
amounts of ATP are required for cell wall biosynthesis; thusby ‘‘nonclassic’’ resistance mechanisms.
the slow growth leads to small colonies, and electron transport
is directly linked to the biosynthesis of carotenoid pigments,
Small Colony Variants
rendering the colonies nonpigmented. The limited hemolysis
and slow coagulase reaction is in part related to decreasedSmall colony variant (SCV) subpopulations of staphylococci
have been described for many decades [11–53]. Aminoglyco- amino acid biosynthesis and uptake (both energy-dependent
processes); consequently, the biosynthesis of nonessential pro-sides and penicillins were recognized as having higher MICs
for some of these organisms [15, 21–24, 26, 27, 29–41, 54– teins for survival appears to be reduced. Biochemical reactions
tested in the clinical microbiology laboratory show use of glu-60], but the mechanism for their increased resistance to antibi-
otics was unclear, and they were described as a heterogeneous cose and fructose but not mannitol or other sugars. Thus, SCVs
are often difficult to recognize as staphylococci, and they maypopulation. Recently, we have proposed that most clinical
SCVs can be tied together by a common thread, which is be misidentified by clinical laboratory personnel [54].
We have very recently reported a site-directed hemB mutantalterations in electron transport [57, 58]. A decrease in electron
transport activity may also account for their resistance to sev- whose phenotype is that of a typical clinical hemin auxotrophic
SCV [59]. The mutant organism grows slowly, is more resistanteral antibiotics as well as provide a mechanism for persisting
within host tissues [57, 58]. to antibiotics than the parent strain, shows reduced coagulase
and hemolytic activity, and is able to persist within culturedMany SCVs are menadione or hemin auxotrophs. Staphylo-
coccal SCVs are defined by colony size 10 times smaller than endothelial cells; in addition, all of the phenotypic changes can
be reversed by complementation with hemB or by the additionthe parent strain [15, 21, 43, 57]. This small size of many
clinical and laboratory SCVs on tryptic soy or Mueller-Hinton of hemin to the growth medium.
Staphylococcal SCVs are more resistant to antibiotics thanagar is often due to auxotrophy for thiamine, menadione, or
hemin [16–18, 23, 24, 29, 42, 46, 49–51, 53–57, 58–61]. the parent strain. An electrochemical gradient is required for
the import of positively charged molecules, such as aminogly-When the medium is supplemented with 1 mg/mL of these
compounds, SCVs grow as rapidly as the parent strains [54– cosides and some lantibiotics, into the bacterium [55, 63]. Lan-
tibiotics are positively charged, lathionine-containing, antibac-60]. The large majority of clinical isolates from our studies
and from studies in the literature are auxotrophic for one of terial peptides that are produced by a number of gram-positive
bacterial species [64]. S. aureus SCVs are more resistant tothese three substances.
lantibiotics and gentamicin [55, 63]. In addition, the slow
growth of these organisms reduces the effectiveness of cell
Electron Transport and SCVs
wall–active antibiotics such as b-lactams [21–23, 30, 34–36,
40]. With menadione or hemin auxotrophic SCVs, the resis-Menadione, hemin, and thiamine are required for biosynthe-
sis of electron transport chain components. Menadione is iso- tance to antibiotics can be reversed by supplying the auxotro-
phic substance [54–59, 63].prenylated to form menaquinone, the acceptor of electrons from
nicotinamide adenine dinucleotide (NADH)/flavin adenine di-
nucleotide (FADH2) in the electron transport chain. Hemin is SCVs and the Clinical Laboratory
required for the biosynthesis of cytochromes, which accept
electrons from menaquinone and complete the electron trans- SCVs present a challenge for susceptibility testing because
the clinical isolates are often a mixed population of parentport chain. Thiamine is required for menadione biosynthesis
[61]; hence, thiamine auxotrophs are also menadione auxo- strains and SCVs [54, 65, 66]. Even a small percentage (e.g.,
0.1%) of normally growing organisms will rapidly replace thetrophs. Many previous reports also noted decreased respiratory
or dye reducing activity in staphylococcal SCVs [16, 17, 23, SCVs in liquid medium in an overnight culture because the
doubling time of normal S. aureus is 20 minutes, whereas24, 29, 41, 49, 62], which is also consistent with reduced
electron transport activity. Therefore, mutants in menadione or SCVs double in180 minutes; hence, the SCVs may be over-
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grown to such an extent that they may not be included in the Antibiotics are not particularly effective against SCVs within
endothelial cells. The activity of antibiotics against an S. aureusinoculum used for susceptibility testing. Furthermore, SCVs are
not always stable once removed from the host, thus providing menadione auxotrophic SCV strain, JB-1 [55], was tested by
adding parent or SCV strains to cultured bovine endothelialanother possibility for not including them in susceptibility test-
ing. On solid medium, the normal colonies are apparent within cells [55]. After 3.5 hours, the monolayers were washed, and
lysostaphin was added to kill the extracellular bacteria. Antibi-18 hours, a time when SCVs are difficult to see. Consequently,
these strains are again easily missed. Because SCVs and normal otics were then added at 0–16 times the MIC, and the cells
were then cultured for another 24 hours in a CO2 incubator.staphylococci have the same appearance on gram stain, there
is no reason to suspect a mixed culture (normal and variant- At 24 hours, a trypsin-EDTA solution was added to loosen the
cells, and the cells were washed in phosphate buffered saline.growth types). With only the wild-type strain being tested, the
more resistant SCV strain is not included in the testing, and a Bacteria were released by lysis of the endothelial cells with
distilled water plus gentle sonication, and plate counts weremajor reporting error will occur.
The slow growth of SCVs makes testing by disk diffusion determined on trypticase soy agar. We found that clarithro-
mycin, clindamycin, ciprofloxacin, and novobiocin plus rifam-or by automated overnight methods invalid because the colo-
nies may be too small to be seen on agar or detected by optical pin were ineffective at killing intracellular SCVs (R. A. Proctor
et al., unpublished observations). Methicillin at 16 times thedensity measurements in automated systems. Testing must be
performed by broth or agar dilution MIC methods. MIC was marginally effective against the parent strain in that
it reduced the number of colonies about one order of magnitude,
but it had little effect on the SCVs. Combining menadione at
2 mg/mL with methicillin increased the killing of S. aureus JB-SCVs, Biopolymers, and Resistance
1 so that it was killed as well as the parent strain.
Trimethoprim-sulfamethoxazole was the most effective anti-S. aureus SCVs are not only more resistant when tested
by classic methods, but they are also much more resistant to biotic, as it usually lowered counts of JB-1 two orders of magni-
tude, but rifampin or ciprofloxacin did not further enhance theantibiotics when adherent to a biopolymer surface [67]. In one
study, during logarithmic growth phase in broth or on solid killing. None of the antibiotics were able to sterilize the infected
monolayer. The finding that a number of antibiotics that pene-phase (i.e., adherent to a polymer surface), both parent and
SCV strains were susceptible to oxacillin, vancomycin, and trate the plasma membrane were ineffective against S. aureus
SCVs was disappointing, but it is consistent with the difficultyfleroxacin; however, two orders of magnitude more of the
SCVs than the parent strain remained alive (1–2 vs. 3–4 log10 in eradicating these organisms in patients [54].
reduction when antibiotics were at eight times the MIC) [67].
In contrast, stationary phase SCVs were much more resistant
Recovery of SCVs from Patients
to killing with only a 10-fold reduction when in fluid phase
and almost no reduction when SCVs were grown on a solid Antibiotic therapy can produce SCVs. S. aureus SCVs can
regularly be harvested when broth cultures are exposed to gen-phase. Of the three antibiotics tested, fleroxacin reduced adher-
ent, stationary phase SCVs almost one log10 , whereas the other tamicin or other aminoglycosides [27, 55]. These variants are
like the clinical isolates in that they are predominantly menadi-antibiotics had essentially no effect on colony counts [67].
Thus, while normal bacteria show a modest decrease in suscep- one and hemin auxotrophs [16, 17, 23, 24, 29, 46, 50, 51, 54,
57]. Anecdotal reports have associated SCVs with the use oftibility when adherent, S. aureus SCVs demonstrate a dramatic
reduction in susceptibility once they are attached to a surface antibiotics, often for prolonged periods, with the recovery of
S. aureus SCVs [15, 21–24, 26, 29–41, 54–60, 65, 66].and have reached stationary phase, such that these adherent
organisms have shown nearly complete resistance to the antibi- The frequency of S. aureus SCVs among clinical isolates
has not been established by prospective studies, except for theotics that have been tested.
Staphylococcal SCVs may persist and resist antibiotic ther- one blood culture study where stable SCVs were recovered
from 1% of patients [18]. Because SCVs can be selected byapy in patients because they can survive within cultured endo-
thelial cells. The reduced production of a-toxin by S. aureus chronic antibiotic exposure, we looked for their presence in
patients chronically exposed to aminoglycosides.SCVs allows these bacteria to persist within mammalian cells
[55, 59]. These variants are phagocytized by cultured endothe- To prospectively study a group of patients who frequently
have staphylococcal infections and receive large quantities oflial cells, yet they do not damage the monolayer [55, 59]. This
can be related to the reduced a-toxin production by S. aureus aminoglycosides, we looked at consecutive cultures for patients
with cystic fibrosis over a 33-month period [65]. We choseSCVs. Similarly, site-directed mutants for a-toxin also persist
within cultured endothelial cells [68]. This location within host patients with cystic fibrosis because S. aureus is the second
most common pathogen isolated from these patients’ sputumcells will shield these variants from host defenses and from
antibiotics that have a limited ability to cross the plasma cell specimens [69], and they receive large quantities of antibiotics.
S. aureus SCVs were recovered from 25% of patients withmembrane.
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cystic fibrosis [65]. A total of 78 SCV strains were recovered The intracellular milieu of mammalian cells can also select
for SCVs. When wild-type S. aureus strains were allowed tofrom these patients and found to be menadione, hemin, and/or
thymidine auxotrophs. Thymidine auxotrophy was the most persist within cultured endothelial cells for 72 hours, SCVs
were harvested at a surprisingly high rate [56]. The SCVsfrequent (53% of strains), and double auxotrophy with thymi-
dine plus hemin auxotrophy was also seen frequently (32%). obtained from cocultivating endothelial cells with S. aureus
were predominantly menadione auxotrophs, and they wereOverall, menadione or hemin auxotrophy were present in 47%
of SCVs. The thymidine auxotrophy probably relates to the more resistant to gentamicin than the normal strain, even
though they had never been exposed to aminoglycosides. Thefrequent and prolonged use of trimethoprim-sulfamethoxazole
as prophylaxis in these patients. The MICs of gentamicin for rate of selection in host tissues exceeded the rate of selection
that can be achieved by exposing S. aureus to positivelythe SCVs were higher, and these organisms were resistant to
trimethoprim-sulfamethoxazole. charged antibiotics in vitro [56]. These observations help to
explain the isolation of S. aureus SCVs from patients who haveAs has been found in other clinical cases and animal models
where SCVs are recovered, the SCVs were able to persist for not received antibiotics [15, 17, 21, 33]. While the mechanism
for SCV production within the intracellular milieu is unknown,a long period in patients with cystic fibrosis [65]. A clinical
hemin auxotrophic SCV isolate from a patient with cystic fi- we have found that a number of positively charged, bactericidal
compounds (i.e., lantibiotics, gentamicin, and protamine) arebrosis was able to persist within cultured endothelial cells [65].
When the SCVs were found in mixed cultures with normally able to select for SCVs (unpublished observations and [63]).
Thus, SCVs can emerge and be more resistant than the parentgrowing S. aureus, either continuously or intermittently, the
normal strain and SCVs proved to be clonal by pulsed-field strain to antibiotics, even in the absence of antibiotic pressure.
gel electrophoretic analysis.
Some care must be exercised in the selection of media for
Potential Therapeutic Advantages to Controlling SCV
susceptibility testing when thymidine auxotrophs are recovered
Formation
because we found that some batches of Mueller-Hinton agar
contained concentrations of thymidine that were high enough While the association of electron transport defects in clinical
SCV isolates occurs quite frequently, the factors that allowto cause reversion of an SCV to the parental phenotype, even
though these batches were claimed to be ‘‘low thymidine.’’ organisms to switch from one phenotype to another are un-
known. Formation of SCVs at a relatively high rate may offerOrganisms with the normal phenotype are more susceptible to
sulfonamide antibiotics [65]. In addition, the slow growth of a survival advantage because they can persist intracellularly
and resist antibiotics. If clinicians were able to control whenSCVs might lead one to consider the use of a more enriched
medium for susceptibility testing (e.g., brain-heart infusion me- the bacteria grow rapidly and when they form SCVs, this might
be therapeutically valuable. For example, reversing the SCVdium; however, this medium contains relatively large amounts
of menadione, which will relieve the SCV phenotype of mena- phenotype by adding menadione enhances susceptibility to an-
tibiotics and decreases the ability of the organisms to residedione auxotrophs).
We monitored S. aureus isolates from patients with osteomy- within cultured cells. Perhaps adding vitamin K (the isopreny-
lated form of menadione) to standard antibiotic regimens mightelitis [66]. This study included four patients with osteomyelitis
who had recurrent disease following surgical placement of gen- reduce the rate of the development of SCVs or prevent the
establishment of SCVs as chronic intracellular pathogens. Thistamicin beads in the infected bones. This represents another
group of patients with chronic exposure to aminoglycosides. might be particularly valuable in the treatment of endovascular
and bone infections, for which therapy currently must be veryBy comparison, no SCVs were recovered from the 10 patients
with S. aureus osteomyelitis who did not receive gentamicin prolonged to assure eradication [10].
Development of the SCV phenotype may not always be abeads, and none of these 10 patients had recurrent disease. The
SCVs were hemin or menadione auxotrophs, and they showed clinically disadvantageous situation. SCVs cause less tissue
damage than do normally growing staphylococci because ofresistance to gentamicin [66]. This study does not necessarily
indicate that gentamicin beads will not provide a net positive their low production of exotoxins, and the presence of SCVs
would be much preferable to that of a highly virulent pathogenvalue in the treatment of osteomyelitis because more patients
may be cured with gentamicin beads than without them. How- in patients with acute bacteremia. The use of drugs that inter-
fered with electron transport might be particularly valuable asever, surgical placement of gentamicin beads essentially repli-
cates the broth culture method for production of SCVs, where a short-term measure if such drugs could rapidly turn off toxin
production. Drugs have been developed that interfere with shik-large numbers of S. aureus are exposed to gentamicin, and
SCVs are produced with great regularity [27, 55]. Thus, if imate metabolism in Escherichia coli, and shikimate is a bio-
synthetic precursor of menadione [70]. We have recently exam-osteomyelitis recurs in patients after the use of gentamicin
beads, clinicians should search especially hard for the presence ined the effects of an electron transport inhibitor on S. aureus
and found that a-toxin production and damage to culturedof SCVs, as they are likely to be more resistant to antibiotic
therapy. endothelial cells was reduced (R. A. Proctor, unpublished ob-
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servations). Drugs such as these would not have to be bacteri- the first challenge is finding and correctly identifying them as
S. aureus. Next, susceptibility testing must be done by agarcidal and would represent a new class of anti–virulence factor
drug. Allowing clinicians to control when S. aureus isolates dilution or by broth MIC methods because the slow growth of
the organisms will not allow accurate determinations by thegrow rapidly and when they are SCVs might reduce the mortal-
ity associated with acute staphylococcal sepsis, reduce the disk diffusion method or automated methods. Susceptibility
testing must be conducted with medium that has low levels oflength of therapy, and increase the rate of clearance of bacteria
from persistently infected patients. thymidine and menadione. The laboratory should be particu-
larly alert for S. aureus SCVs when samples come from patients
who have received long-term therapy or when an infectiousSCVs in Other Species
disease has been unusually persistent, antibiotic resistant, or
The emphasis of this review has been on S. aureus; however, recurrent. However, the host milieu can select for S. aureus
coagulase-negative staphylococci have been reported to form SCVs, which means that patients may have SCVs even when
SCVs, and these strains have been particularly difficult to clear they have not received antibiotic therapy. The presence of sub-
from infected heart valves [35, 71]. Furthermore, a wide variety populations of bacteria that are able to persist within host cells
of other species are known to form SCVs (e.g., Pseudomonas also reemphasizes that the determination of MICs has major
aeruginosa, Salmonella typhimurium, Shigella species, Bru- limitations for predicting efficacy of a drug. Finally, when these
cella abortus, E. coli, Lactobacillus acidophilus, Serratia variant bacteria are established in stationary phase and adherent
marcescens, and Neisseria gonorrhoeae) [72–80]. Many of the to surfaces, they are exceptionally resistant to antibiotics.
SCVs from these species are described as respiratory deficient
and/or have been characterized as deficient in electron transport
[73–76, 79, 80]. These SCVs also display increased resistance
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